Get the Stockscreener App
3.795
0.13%
-0.005
Qualigen Therapeutics Inc stock is traded at $3.795, with a volume of 818.
It is down -0.13% in the last 24 hours and up +6.01% over the past month.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
See More
Previous Close:
$3.80
Open:
$3.76
24h Volume:
818
Relative Volume:
0.01
Market Cap:
$2.76M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-1.4267
EPS:
-2.66
Net Cash Flow:
$-10.30M
1W Performance:
+0.57%
1M Performance:
+6.01%
6M Performance:
-17.81%
1Y Performance:
-72.22%
1-Day Range:
$3.735
$3.79
1-Week Range:
$3.65
$3.90
52-Week Range:
$2.85
$29.43
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
(760) 918-9165
Address
2042 CORTE DEL NOGAL, CALIFORNIA
Compare QLGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
3.735 | 2.79M | 4.79M | -13.42M | -10.30M | -2.66 |
|
ONC
Beone Medicines Ltd Adr
|
247.37 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.61 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.42 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.16 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Qualigen Therapeutics Faces Nasdaq Delisting Notification - MSN
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 2.1% – Should You Sell? - Defense World
Qualigen Therapeutics Receives Nasdaq Deficiency Notice - marketscreener.com
Qualigen Therapeutics, Inc. receives expected notification of de - GuruFocus
Qualigen Therapeutics receives Nasdaq notice regarding delayed Form 10-Q - MSN
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q | QLGN Stock News - GuruFocus
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q - The Manila Times
Qualigen Therapeutics, Inc. Receives Expected Notification Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Report On Form 10-Q - marketscreener.com
Qualigen Therapeutics faces potential Nasdaq delisting - Investing.com
Qualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing Deficiency - Nasdaq
Qualigen Therapeutics, Inc. receives expected notification - GlobeNewswire
Qualigen Gets Nasdaq Warning: Missing Q1 Report Puts Stock Listing in Jeopardy - Stock Titan
Qualigen Therapeutics (QLGN) Faces Nasdaq Compliance Challenge | - GuruFocus
Qualigen Therapeutics, Inc. Receives Notification of Deficiency - GuruFocus
Qualigen Therapeutics Faces Nasdaq Delisting Threat - TipRanks
Qualigen Therapeutics, Inc. Faces Nasdaq Delisting Due to Late Filing of 2024 Form 10-K - Nasdaq
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K - TradingView
QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN
Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - GlobeNewswire
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com UK
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics Appoints Graydon Bensler to Board - TipRanks
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):